Altogether, this study indicates that reducing extracellular CDA activity (CDA is not only present inside cells but also in human plasma) may provide a means to increase the therapeutic index of DHODHi especially in patients with cancers where CDA expression is low. The gene discussed is CDA; the disease is cancer.